Diagnosed cases of diabetic macular edema across 7MM to reach 3.46 million in 2034
The diagnosed prevalent cases of diabetic macular edema (DME) in the diabetes population across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan) are expected to increase at an annual growth rate (AGR) of 1.99% from 2.89 million in 2024 to 3.46 million in 2034, forecasts pharma analytics analytics company GlobalData.
GlobalData’s report, “Diabetic Macular Edema (DME) – Epidemiology Forecast to 2034,” reveals that the US will have the highest number of diagnosed prevalent cases of DME in diabetes among the 7MM at 1.01 million, whereas Japan will have the lowest number at 0.13 million cases in 2034.
Antara Bhattacharya, associate project manager, epidemiology at GlobalData, comments: “In 2024, the disease burden in the 7MM showed a clear gender skew, with men accounting for around 57% of cases compared with 43% among women.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze